Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Leukemia & Lymphoma|February 6, 2021
Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 monthsAino Rajamäki, Kaisa Sunela, Roosa E I Prusila, et al.
Cancer Medicine|May 11, 2026
Socioeconomic Status and Access to Treatment in Diffuse Large B-Cell LymphomaKuitunen Joonas, Marin Katja, Tokola Susanna, et al.
Annals of Hematology|December 19, 2024
Defining MRI-based follow-up protocol for primary central nervous system lymphomaInka K Puhakka, Kaisa L Sunela, Aino L Rönkä, et al.
Cancer Medicine|November 23, 2025
Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell LymphomaSusanna Tokola, Katja Marin, Milla E L Kuusisto, et al.
Basic & Clinical Pharmacology & Toxicology|April 28, 2025
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre TrialSari Kytölä, Mika Kurkela, Johanna I Kiiski, et al.
Acta Oncologica (Stockholm, Sweden)|August 2, 2019
Incidence of solid cancer in patients with follicular lymphomaMarc Sorigue, Roosa E I Prusila, Jyrki Jauhiainen, et al.
British Journal of Haematology|July 4, 2019
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab eraRoosa E I Prusila, Marc Sorigue, Jyrki Jauhiainen, et al.
Blood|October 2, 2024
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trialSari Kytölä, Ida Vänttinen, Tanja Ruokoranta, et al.
Haematologica|December 15, 2022
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemiaHeikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, et al.
Pageof 3